Like 2 years ago, the panellists were asked to vote on the advisability of genetic testing for high risk (germ-line) mutations after counselling for several subtypes of patients with early breast cancer. In general, the panellists were more inclined to advise genetic testing compared to 2 years ago. There was absolute consensus (100% of the panellists voted “yes”) that all patients with a strong family history should be offered genetic testing. In addition, almost all panellists (96%) endorsed genetic testing in all patients who are younger than 35 years. A vast majority of the panellists (85%) was in favour of genetic testing in all patients with triple-negative breast cancer who are 60 years or younger at the time of diagnosis. However, only 39% of the panellists endorsed genetic testing in all patients with triple-negative breast cancer (regardless of their age); 33% of the panellists endorsed genetic testing in all patients with breast cancer who are younger than 50 years and...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Prostate Cancer: What to Expect the next 12 Months Next Article
Dactolisib Phase 2b Clinical Trial Data Shows Reduction of Respiratory Tract Infections in Senior Asthma Patients »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.